Researcher
Eline Menu
- Research Expertise:
- Research for therapies, targeting the myeloma cell in its microenvironment
- Keywords:Medicine
- Disciplines:Hematology, Cell signalling, Cellular interactions and extracellular matrix, Cancer biology
- Users of research expertise:
- Research for therapies, targeting the myeloma cell in its microenvironment
Affiliations
- Hematology (Research group)
Member
From1 Oct 2001 → Today - Basic (bio-) Medical Sciences (Department)
Member
From1 Oct 2020 → Today - Basic (bio-) Medical Sciences (Department)
Member
From8 Apr 2019 → 30 Sep 2020 - Faculty of Medicine and Pharmacy (Faculty)
Member
From22 Jun 2017 → 7 Sep 2017 - Basic (bio-) Medical Sciences (Department)
Member
From1 Jan 2014 → 20 Oct 2022 - Basic (bio-) Medical Sciences (Department)
Member
From1 Jan 2014 → 30 Sep 2015 - Immunology and Microbiology (Department)
Member
From1 Nov 2009 → 31 Dec 2013 - Immunology and Microbiology (Department)
Member
From1 Oct 2001 → 31 Dec 2013
Projects
1 - 10 of 10
- SRP-Onderzoekszwaartepunt: PACT: multi-omics Profiling of T cells to improve Adoptive Cell TherapyFrom1 Nov 2022 → TodayFunding: BOF - projects
- Seahorse platform: the Agilent Seahorse Flux Analyser with integrated normalization systemFrom1 May 2020 → TodayFunding: Hercules - Small and Medium size research infrastructure
- Targeting the hypoxia-induced metabolic changes in multiple myeloma to conquer drug resistance.From1 Oct 2019 → 31 Jan 2024Funding: FWO fellowships
- advanced Metabolomics Platform consisting of two complementary LC-MS/MS analyzersFrom1 May 2016 → 30 Apr 2020Funding: Hercules - Small and Medium size research infrastructure
- Modulation of the tumor micro-environment in Multiple Myeloma, are exosomes involved?From1 Jan 2016 → 31 Dec 2019Funding: FWO research project (including WEAVE projects)
- Drug resistance in multiple myeloma: study of extrinsic mechanisms governed by the bone marrow microenvironmentFrom1 Jan 2014 → 31 Dec 2017Funding: FWO research project (including WEAVE projects)
- NKT cells as a target for treatment in Multiple MyelomaFrom1 Jan 2012 → 31 Dec 2014Funding: FWO research project (including WEAVE projects)
- Pre-clinical evaluation of NKT-cells in multiple myelomaFrom1 Jan 2011 → 31 Dec 2011Funding: FWO research grant KAN
- Tumor-microenvoronment interactions in multiple myeloma: regulation by epigenetic modifications and hypoxia.From1 Jan 2010 → 31 Dec 2013Funding: FWO research project (including WEAVE projects)
- The role of IGF-1 in Multiple Myeloma tumor progression: effects on cell cycle and UPR responseFrom1 Jan 2009 → 31 Dec 2009Funding: FWO research grant KAN
Publications
1 - 10 of 46
- RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma(2023)
Authors: Martina Emde-Rajaratnam, Susanne Beck, Vladimir Benes, Hans Jürgen Salwender, Uta Bertsch, Christoph Scheid, Mathias Hänel, Katja Weisel, Thomas Hielscher, Marc S Raab, et al.
- Metformin confers sensitisation to syrosingopine in multiple myeloma cells by metabolic blockage and inhibition of protein synthesis(2023)
Authors: Arne Van der Vreken, Inge Oudaert, Gamze Ates, Sylvia Faict, Philip Vlummens, Hatice Satilmis, Rong Fan, Anke Maes, Ann Massie, Kim De Veirman, et al.
Pages: 112-123 - Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma(2023)
Authors: Rong Fan, Hatice Satilmis, Niels Vandewalle, Emma Verheye, Philip Vlummens, Anke Maes, Catharina Muylaert, Elke De Bruyne, Eline Menu, Holly Evans, et al.
- Targeting the β2 -adrenergic receptor increases chemosensitivity in multiple myeloma by induction of apoptosis and modulating cancer cell metabolism(2023)
Authors: Hatice Satilmis, Emma Verheye, Philip Vlummens, Inge Oudaert, Niels Vandewalle, Rong Fan, Jennifer M Knight, Nathan De Beule, Gamze Ates, Ann Massie, et al.
Pages: 69–80 - The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers(2022)
Authors: Rong Fan, Nathan De Beule, Anke Maes, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Ken Maes, Karine Breckpot, Kim De Veirman
- Aberrant DNA methylation in multiple myeloma(2022)
Authors: Catharina Muylaert, Lien Ann Van Hemelrijck, Anke Maes, Kim De Veirman, Eline Menu, Karin Vanderkerken, Elke De Bruyne
- System Xc- inhibition blocks bone marrow-multiple myeloma exosomal crosstalk, thereby countering bortezomib resistance(2022)
Authors: Fang Wang, Inge Oudaert, Chenggong Tu, Anke Maes, Arne Van der Vreken, Philip Vlummens, Elke De Bruyne, Kim De Veirman, Yanmeng Wang, Rong Fan, et al.
- Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis(2022)
Authors: Inge Oudaert, Hatice Satilmis, Philip Vlummens, Wouter De Brouwer, Anke Maes, Dirk Hose, Elke De Bruyne, Bart Ghesquière, Karin Vanderkerken, Kim De Veirman, et al.
Pages: 45 - Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions(2022)
Authors: Jesús Bravo Melgar, Sofie Deschoemaeker, Geert Raes, Anke Maes, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Damya Laoui, Kim De Veirman
- Targeting coenzyme Q10 synthesis overcomes bortezomib resistance in multiple myeloma(2022)
Authors: Esther Zaal, Harm Jan De Groot, Inge Oudaert, Eline Menu, Celia R. Berkers
Pages: 19-30